Veeva Systems earnings release, August 26, 2026

Veeva Systems Inc (VEEV) · Form 8-K, Item 2.02 · Filed · SEC filing

Veeva Announces Fiscal 2027 Second Quarter Results

Total Revenues of $928.0M, up 18% Year Over Year

Subscription Revenues of $766.8M, up 16% Year Over Year

PLEASANTON, CA — August 26, 2026 — Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2026.

“AI is opening up the next big chapter for Veeva and life sciences,” said CEO Peter Gassner. “Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. By bringing together deep industry applications, agents, data, and consulting, we are helping the industry drive new efficiencies from clinical to commercial and deliver better outcomes for patients.”

Fiscal 2027 Second Quarter Results:

• Revenues

: Total revenues for the second quarter were $928.0 million, up from $789.1 million one year ago, an increase of 18% year over year. Subscription revenues for the second quarter were $766.8 million, up from $659.2 million one year ago, an increase of 16% year over year.

• Operating Income and Non-GAAP Operating Income

:

(1)

Second quarter operating income was $275.0 million, compared to $195.9 million one year ago, an increase of 40% year over year. Non-GAAP operating income for the second quarter was $415.9 million, compared to $352.6 million one year ago, an increase of 18% year over year.

• Net Income and Non-GAAP Net Income

:

(1)

Second quarter net income was $273.4 million, compared to $200.3 million one year ago, an increase of 37% year over year. Non-GAAP net income for the second quarter was $387.4 million, compared to $333.4 million one year ago, an increase of 16% year over year.

• Net Income per Share and Non-GAAP Net Income per Share

:

(1)

For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago.

“Second quarter results exceeded guidance on all metrics and our view for the full year improved across the board,” said CFO Brian Van Wagener. “We continue to execute well across the business while also accelerating innovation and progress in new growth areas.”

Recent Highlights:

• Vault CRM Leadership Grows with More Top 20 Wins, Go-lives, and AI Adoption – Vault CRM leadership grew with more than 180 customers live, including five top 20 biopharmas. In August, two top 20 biopharmas and one large enterprise biopharma committed to Vault CRM, bringing total top 20 commitments to 12 globally. As the industry's fastest path to agentic CRM, a top 20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team in the quarter.

• Major AI Milestones for Vault AI and Falcon, and Agentic MLR Launches – Veeva AI advanced rapidly across all areas. Development of Veeva Falcon, the agentic labor platform for clinical, regulatory, and safety, is moving quickly with five early adopters and on track for initial go-lives this year. The company also acquired Copli in the quarter and launched Veeva Falcon MLR to automate content reviews. August marked a major milestone for Vault AI with new standard agents, broader capabilities for existing agents, and advanced tools for custom agent development.

• Delivering the Connected Foundation for R&D and Quality – Development Cloud and Quality Cloud saw broad adoption, deepening relationships with new and existing customers. In clinical, a large enterprise biopharma selected Veeva EDC, building on its existing eTMF, CTMS, and Study Startup foundation. Veeva Safety surpassed 100 total customers while securing its second top 20 biopharma win for Safety Workbench. In Quality, Veeva added more than 30 new customers, driven by 20 or more wins each across QualityDocs, QMS, and Training.

Financial Outlook:

Veeva is providing guidance for its fiscal third quarter ending October 31, 2026 as follows:

• Total revenues between $932 and $935 million.

• Non-GAAP operating income between $417 and $420 million.

(2)

• Non-GAAP fully diluted net income per share between $2.33 and $2.34.

(2)

Veeva is providing updated guidance for its fiscal year ending January 31, 2027 as follows:

• Total revenues between $3,682 and $3,687 million.

• Non-GAAP operating income of about $1,640 million.

(2)

• Non-GAAP fully diluted net income per share of approximately $9.21.

(2)

Conference Call Information

Prepared remarks and an investor presentation providing additional information and analysis can be found on Veeva's investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, August 26, 2026, and a replay of the call will be available on Veeva's investor relations website.

___________

(1)

This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled

“

Non-GAAP Financial Measures” and the tables entitled

“

Reconciliation of GAAP to Non-GAAP Financial Measures” below for details.

(2)

Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the third fiscal quarter ending October 31, 2026 or the fiscal year ending January 31, 2027 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

About Veeva Systems... (truncated)ng customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Financial statements

Income Statement

Three months ended July 31, — (Unaudited)

Three months ended July 31, – 2026Three months ended July 31, – 2025Six months ended July 31, – 2026Six months ended July 31, – 2025
Revenues:Subscription(3)766,764659,1831,496,9391,293,951
Revenues:Professional services and other(4)161,199129,898313,972254,173
Revenues:Total revenues927,963789,0811,810,9111,548,124
Cost of revenues(5):Cost of subscription105,67793,830204,780172,176
Cost of revenues(5):Cost of professional services and other126,335101,423248,156196,901
Cost of revenues(5):Total cost of revenues232,012195,253452,936369,077
Cost of revenues(5):Gross profit695,951593,8281,357,9751,179,047
Operating expenses(5):Research and development222,918192,677431,241376,710
Operating expenses(5):Sales and marketing126,701109,439237,818208,067
Operating expenses(5):General and administrative71,31495,804140,786164,630
Operating expenses(5):Total operating expenses420,933397,920809,845749,407
Operating expenses(5):Operating income275,018195,908548,130429,640
Operating expenses(5):Other income, net74,51269,456148,930134,545
Operating expenses(5):Income before income taxes349,530265,364697,060564,185
Operating expenses(5):Income tax provision76,10165,055162,695135,686
Operating expenses(5):Net income273,429200,309534,365428,499
Net income per share:Basic1.681.233.282.63
Net income per share:Diluted1.661.193.222.56
Weighted-average shares used to compute net income per share:Basic162,344163,496162,836163,129
Weighted-average shares used to compute net income per share:Diluted165,057167,685166,072167,272
Other comprehensive income:Net change in unrealized (loss) gain on available-for-sale investments-26,490-11,300-53,9416,067
Other comprehensive income:Net change in cumulative foreign currency translation gain (loss)135390-366352
Other comprehensive income:Comprehensive income247,074189,399480,058434,918
(3) Includes subscription revenues from the following product areas:Veeva Commercial Solutions347,389307,523685,255612,934
(3) Includes subscription revenues from the following product areas:Veeva R&D and Quality Solutions419,375351,660811,684681,017
(3) Includes subscription revenues from the following product areas:Total subscription766,764659,1831,496,9391,293,951
(4) Includes professional services and other revenues from the following product areas:Veeva Commercial Solutions59,74247,703117,31594,270
(4) Includes professional services and other revenues from the following product areas:Veeva R&D and Quality Solutions101,45782,195196,657159,903
(4) Includes professional services and other revenues from the following product areas:Total professional services and other161,199129,898313,972254,173
Cost of revenues:Cost of subscription2,2241,9413,9853,656
Cost of revenues:Cost of professional services and other15,93914,80430,09027,573
Cost of revenues:Research and development62,22053,388113,783101,337
Cost of revenues:Sales and marketing27,88625,39252,48047,713
Cost of revenues:General and administrative28,53426,44155,72453,897
Cost of revenues:Total stock-based compensation136,803121,966256,062234,176

Income Statement

Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to non-G — The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Three months ended July 31, – 20262026Three months ended July 31, – 202620262025Three months ended July 31, – 20252025Six months ended July 31, – 20262026Six months ended July 31, – 202620262025Six months ended July 31, – 20252025
Net cash provided by operating activities on a GAAP basis238,709238,4331,365,8251,115,591
Excess tax (benefit) deficiency from employee stock plans-3,268-13,031824-15,610
Net cash provided by operating activities on a non-GAAP basis235,441225,4021,366,6491,099,981
Net cash used in investing activities on a GAAP basis-63,540-389,272-452,251-441,379
Net cash (used in) provided by financing activities on a GAAP basis-259,308115,689-521,834136,069
Reconciliation of Financial Measures (GAAP basis to non-GAAP basis)Three months ended July 31,Six months ended July 31,
Cost of subscription revenues on a GAAP basis105,67793,830204,780172,176
Stock-based compensation expense-2,224-1,941-3,985-3,656
Amortization of purchased intangibles-1,072-1,046-1,746-2,058
Cost of subscription revenues on a non-GAAP basis102,38190,843199,049166,462
Gross margin on subscription revenues on a GAAP basis86.285.886.386.7
Stock-based compensation expense0.30.30.30.3
Amortization of purchased intangibles0.10.10.10.1
Gross margin on subscription revenues on a non-GAAP basis86.686.286.787.1
Cost of professional services and other revenues on a GAAP basis126,335101,423248,156196,901

Income Statement

Three months ended July 31, — (Unaudited)

Three months ended July 31, – 2026Three months ended July 31, – 2025Six months ended July 31, – 2026Six months ended July 31, – 2025
Sales and marketing expense on a GAAP basis126,701109,439237,818208,067
Stock-based compensation expense-27,886-25,392-52,480-47,713
Amortization of purchased intangibles-2,720-2,890-5,051-5,685
Sales and marketing expense on a non-GAAP basis96,09581,157180,287154,669
General and administrative expense on a GAAP basis71,31495,804140,786164,630
Stock-based compensation expense-28,534-26,441-55,724-53,897
Litigation settlement-related charges-30,627-30,627
General and administrative expense on a non-GAAP basis42,78038,73685,06280,106
Operating expense on a GAAP basis420,933397,920809,845749,407
Stock-based compensation expense-118,640-105,221-221,987-202,947
Amortization of purchased intangibles-2,990-2,890-5,321-5,685
Litigation settlement-related charges-30,627-30,627
Operating expense on a non-GAAP basis299,303259,182582,537510,148
Operating income on a GAAP basis275,018195,908548,130429,640
Stock-based compensation expense136,803121,966256,062234,176
Amortization of purchased intangibles4,0624,0757,0678,016
Litigation settlement-related charges30,62730,627
Operating income on a non-GAAP basis415,883352,576811,259702,459
Operating margin on a GAAP basis29.624.830.327.8
Stock-based compensation expense14.715.514.115.1
Amortization of purchased intangibles0.50.50.40.5
Litigation settlement-related charges3.92
Operating margin on a non-GAAP basis44.844.744.845.4
Net income on a GAAP basis273,429200,309534,365428,499
Stock-based compensation expense136,803121,966256,062234,176
Amortization of purchased intangibles4,0624,0757,0678,016
Litigation settlement-related charges30,62730,627
Income tax effect on non-GAAP adjustments(6)-26,882-23,572-38,945-40,085
Net income on a non-GAAP basis387,412333,406758,549661,234
Diluted net income per share on a GAAP basis1.661.193.222.56
Stock-based compensation expense0.830.731.541.4
Amortization of purchased intangibles0.020.020.040.05
Litigation settlement-related charges0.180.18
Income tax effect on non-GAAP adjustments(6)-0.16-0.13-0.23-0.24
Diluted net income per share on a non-GAAP basis2.351.994.573.95

Balance Sheet

(Unaudited)

July 31, 2026January 31, 2026
Current assets:Cash and cash equivalents1,812,0121,421,233
Current assets:Short-term investments5,430,9355,139,581
Current assets:Accounts receivable, net496,6771,259,737
Current assets:Unbilled accounts receivable68,97050,609
Current assets:Prepaid expenses and other current assets137,633126,470
Current assets:Total current assets7,946,2277,997,630
Current assets:Property and equipment, net79,48370,261
Current assets:Deferred costs, net27,83529,961
Current assets:Lease right-of-use assets129,32075,626
Current assets:Goodwill492,991439,877
Current assets:Intangible assets, net55,64730,314
Current assets:Deferred income taxes268,250273,417
Current assets:Other long-term assets60,47062,257
Current assets:Total assets9,060,2238,979,343
Current liabilities:Accounts payable35,97737,644
Current liabilities:Accrued compensation and benefits42,18845,857
Current liabilities:Accrued expenses and other current liabilities49,63445,885
Current liabilities:Income tax payable3,0186,698
Current liabilities:Deferred revenue1,310,4981,488,819

Cash Flow

Six months ended July 31, — (Unaudited)

Six months ended July 31, – 20262025
Cash flows from operating activitiesNet income534,365428,499
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization22,45819,948
Adjustments to reconcile net income to net cash provided by operating activities:Reduction of lease right-of-use assets7,0386,316
Adjustments to reconcile net income to net cash provided by operating activities:Accretion of discount on short-term investments-2,841-4,535
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation256,062234,176
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of deferred costs9,8058,205
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes26,52931,699
Adjustments to reconcile net income to net cash provided by operating activities:Other, net-1,127-1,414
Changes in operating assets and liabilities:Accounts receivable768,314593,032
Changes in operating assets and liabilities:Unbilled accounts receivable-18,361-9,587
Changes in operating assets and liabilities:Deferred costs-7,679-7,721
Changes in operating assets and liabilities:Prepaid expenses and other current and long-term assets-21,394-21,232
Changes in operating assets and liabilities:Accounts payable-6523,361
Changes in operating assets and liabilities:Accrued expenses and other current liabilities-1,57823,763
Changes in operating assets and liabilities:Income tax payable-3,945-5,362
Changes in operating assets and liabilities:Deferred revenue-200,001-180,888
Changes in operating assets and liabilities:Lease liabilities-4,426-5,300
Changes in operating assets and liabilities:Other long-term liabilities3,2582,631
Changes in operating assets and liabilities:Net cash provided by operating activities1,365,8251,115,591
Cash flows from investing activitiesPurchases of short-term investments-1,706,632-1,452,857
Cash flows from investing activitiesMaturities and sales of short-term investments1,345,9871,023,691
Cash flows from investing activitiesLong-term assets-9,773-12,213
Cash flows from investing activitiesAcquisitions, net of cash acquired-81,833
Cash flows from investing activitiesNet cash used in investing activities-452,251-441,379
Cash flows from financing activitiesProceeds from exercise of common stock options17,143182,297
Cash flows from financing activitiesRepurchases of common stock-472,673
Cash flows from financing activitiesTaxes paid related to net share settlement of equity awards-66,304-46,228
Cash flows from financing activitiesNet cash (used in) provided by financing activities-521,834136,069
Cash flows from financing activitiesEffect of exchange rate changes on cash, cash equivalents, and restricted cash-8311,365
Cash flows from financing activitiesNet change in cash, cash equivalents, and restricted cash390,909811,646
Cash flows from financing activitiesCash, cash equivalents, and restricted cash at beginning of period1,423,4121,120,963
Cash flows from financing activitiesCash, cash equivalents, and restricted cash at end of period1,814,3211,932,609
Supplemental disclosures of other cash flow information:Excess tax (deficiency) benefit from employee stock plans-82415,610
Full release

Forward-looking Statements

This release contains forward-looking statements regarding Veeva’s expected future performance and, in particular, includes quotes from management and guidance, provided as of August 26, 2026, about Veeva’s expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance.

There are also numerous risks that have the potential to negatively impact our financial performance, including issues related to the performance, availability, security, or privacy of our products, competitive factors, customer decisions and priorities, developments that impact the life sciences industry (including regulatory, funding, or policy changes), general macroeconomic and geopolitical events (including changes in trade policy or practices, inflationary pressures, currency exchange fluctuations, changes in interest rates, and geopolitical conflicts), and issues that impact our ability to hire, retain and adequately compensate talented employees. We have summarized what we believe are the principal risks to our business in a section titled “Summary of Risk Factors” on pages 33 and 34 in our filing on Form 10-Q for the period ended

April 30, 2026 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-Q and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.

###

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Veeva Systems earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.